GQG Partners’s Amedisys AMED Stock Holding History

GQG Partners’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-991	Closed	-$243K	–	86
2021 Q2	$243K	Buy	+991	New	+$260K	﹤0.01%	80

Other funds holding AMED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GQG Partners's AMED Position: Q3 2021 in Review

GQG Partners sold out of Amedisys (AMED) in Q3 2021, closing a stake of 991 shares — an estimated $243K sold.

GQG Partners first reported a position in AMED in Q2 2021 and held it in 1 quarter. The position peaked at $243K in Q2 2021. 352 funds tracked by Wall St. Rank hold AMED as of Q3 2021.

GQG Partners reported no remaining Amedisys position as of Q3 2021 after selling out during the quarter.
GQG Partners sold 991 Amedisys shares in Q3 2021, an estimated $243K.
GQG Partners first reported a position in Amedisys in Q2 2021 and held it in 1 quarter.
GQG Partners's Amedisys position peaked at $243K in Q2 2021.
352 funds tracked by Wall St. Rank held Amedisys as of Q3 2021.

Based on GQG Partners's 13F filing for Q3 2021, filed 16 Nov 2021.